Drugs / CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07112053 | Nov 2025 → Jul 2028 expected | female breast carcinoma, hormone receptor-positive breast cancer | University of Washington | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07112053 ↗ |
| Action | Deplete | “boosting the immune system to recognize and destroy the invader tumor cells” NCT07112053 ↗ |
| Modality | Vaccine | “a vaccine, STEMVAC, works in combination” NCT07112053 ↗ |
| Route | Other | “patients receive STEMVAC intradermally (ID)” NCT07112053 ↗ |